Researchers have identified a critical link between the NLRP3 inflammasome – a key component of the brain’s immune response – and the progression of Alzheimer’s disease. A study published in Frontiers in Immunology in April 2025, alongside corroborating research from the past two decades, demonstrates that activation of the NLRP3 inflammasome contributes to the accumulation of amyloid-beta plaques, tau hyperphosphorylation, and subsequent neuronal damage.
The NLRP3 inflammasome, when activated, triggers the release of inflammatory molecules like IL-1β. Previous work, including a 2013 study in Nature by Heneka et al., showed that mice genetically engineered to lack NLRP3 exhibited reduced amyloid-beta deposition and were protected from neuroinflammation and cognitive impairment. This protective effect was observed in the APP/PS1 mouse model, a commonly used animal model of Alzheimer’s disease.
More recent findings, published in Cell in 2025, reveal that NLRP3 activation isn’t solely tied to the release of inflammatory signals. Researchers discovered that amyloid-beta deposition directly triggers NLRP3 activation, leading to alterations in microglial metabolism. Specifically, NLRP3 activation influences glutaminolysis, a metabolic pathway, which in turn affects the ability of microglia – the brain’s resident immune cells – to clear cellular debris through phagocytosis. This suggests a more complex role for NLRP3 than previously understood.
Microglia play a dual role in Alzheimer’s disease. Initially, they attempt to clear amyloid-beta plaques, but chronic activation can lead to a detrimental inflammatory response. Studies indicate that NLRP3 inflammasome deficiency can shift microglia towards an M2 phenotype, considered more beneficial for clearing amyloid-beta and promoting tissue repair, as demonstrated in the APP/PS1 model. However, the precise mechanisms governing this shift and the long-term consequences remain under investigation.
The involvement of D-serine, a co-agonist of the NMDA receptor, adds another layer of complexity. Amyloid-beta peptide induces the expression of serine racemase in microglia, leading to increased D-serine release. Excessive D-serine can contribute to excitotoxicity, potentially damaging neurons. Research indicates that inhibiting serine racemase may offer neuroprotective benefits, with studies showing attenuation of cerebral ischemia and excitotoxicity in knockout mice. A 2023 study found regional contributions of D-serine to Alzheimer’s disease pathology in male mice.
Emerging research highlights sex-specific differences in microglial function and Alzheimer’s disease progression. Studies have shown variations in the phagocytic activity of microglia between males and females, and these differences can be influenced by hormones like follicle-stimulating hormone (FSH). A 2022 Nature study demonstrated that blocking FSH improved cognition in mice with Alzheimer’s disease, particularly in females. These findings suggest that therapeutic strategies may need to be tailored based on sex.
Recent investigations are also focusing on histone lactylation, a novel epigenetic modification, and its role in regulating microglial function. Researchers have found that histone lactylation boosts gene activation involved in repair processes following myocardial infarction, and similar mechanisms may be at play in the brain. Specifically, histone lactylation appears to regulate microglial glucose metabolism, which is disrupted in Alzheimer’s disease.
The TREM2-APOE pathway is also gaining attention as a key regulator of microglial dysfunction in neurodegenerative diseases. Studies have shown that TREM2, a receptor expressed on microglia, influences the transcriptional phenotype of these cells, and its interaction with APOE4, a major genetic risk factor for Alzheimer’s disease, can contribute to disease pathology. Further research is needed to fully elucidate the interplay between these factors and their potential as therapeutic targets.
Despite these advances, the precise mechanisms linking NLRP3 activation, microglial dysfunction, and Alzheimer’s disease progression remain incompletely understood. Researchers continue to investigate the potential of targeting the NLRP3 inflammasome as a therapeutic intervention, but clinical trials are still needed to determine the efficacy and safety of such approaches. The role of D-serine and serine racemase inhibition is also being explored as a potential therapeutic strategy, with ongoing studies evaluating the effects of topical inhibitors on choroidal vasculopathy.
